A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)

Stopped early · Phase 4

Conditions studied: Myocardial Infarction

In brief

To show whether addition of thrombolytic treatment by a single bolus injection of tenecteplase prior to early standard PCI (percutaneous coronary intervention) will improve the clinical outcome in patients with large acute myocardial infarcts as compared to primary PCI alone.

Key facts

Study ID

NCT00168792

Run by

Boehringer Ingelheim

People needed

1671

Starts

2003-11-01

Last updated by the study team

2013-10-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients giving informed consent
• Patients with a large acute myocardial infarction randomised within 6 hours of symptom onset
• Patients scheduled to undergo primary PCI
• Patients reaching the cath lab not before 60 min and not later than 3 hours after randomisation
• (Otherwise the patients fulfill the usual selection criteria for thrombolytic treatment and PCI)
• Exclusion Criteria: None

Where it is running

• Boehringer Ingelheim Investigational Site — Fort Lauderdale, Florida, United States
• Boehringer Ingelheim Investigational Site — St. Petersburg, Florida, United States
• Boehringer Ingelheim Investigational Site — Tampa, Florida, United States
• Boehringer Ingelheim Investigational Site — Macan, Georgia, United States
• Boehringer Ingelheim Investigational Site — Detroit, Michigan, United States
• Boehringer Ingelheim Investigational Site — Omaha, Nebraska, United States
• Boehringer Ingelheim Investigational Site — Providence, Rhode Island, United States
• Boehringer Ingelheim Investigational Site — Feldkirch, Austria
• Boehringer Ingelheim Investigational Site — Sankt Pölten, Austria
• Boehringer Ingelheim Investigational Site — Vienna, Austria
• Boehringer Ingelheim Investigational Site — Wiener Neustadt, Austria
• Boehringer Ingelheim Investigational Site — Aalst, Belgium
• Boehringer Ingelheim Investigational Site — Anderlecht, Belgium
• Boehringer Ingelheim Investigational Site — Angleur, Belgium
• Boehringer Ingelheim Investigational Site — Antwerp, Belgium
• Boehringer Ingelheim Investigational Site — Bonheiden, Belgium
• Boehringer Ingelheim Investigational Site — Bouge, Belgium
• Boehringer Ingelheim Investigational Site — Bruges, Belgium
• Boehringer Ingelheim Investigational Site — Brussels, Belgium
• Boehringer Ingelheim Investigational Site — Charleroi, Belgium
• Boehringer Ingelheim Investigational Site — Genk, Belgium
• Boehringer Ingelheim Investigational Site — Ghent, Belgium
• Boehringer Ingelheim Investigational Site — Gilly, Belgium
• Boehringer Ingelheim Investigational Site — Huy, Belgium
• Boehringer Ingelheim Investigational Site — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.